{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:56:43Z","timestamp":1789750603180,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Hepatoblastoma (HB) tumor rupture is currently considered as a high-risk factor in some risk stratification systems. This study aimed to investigate the value of HB tumor rupture in predicting the poor prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical data from children with high-risk HB or HB tumor rupture at our institution from October 2008 to 2017 were retrospectively reviewed and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Together, 34 children with high-risk HB or HB tumor rupture were retrospected, including 25 in the high-risk group and nine in tumor rupture group. The 3-year overall survival (OS) rate in tumor rupture group was significantly higher than that of the high-risk group (100 vs. 64%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0427). In tumor rupture group, seven (77.8%) of nine patients had a hemoglobin level \u2264 8 g\/L and 3 of them (33.3%) had \u2264 6 g\/L at the time of diagnosis. Peritoneal perfusion with interleukin-2 was implemented for each patient. At the end of the treatment, seven (77.8%) of nine patients achieved complete response (CR). No patient died at the last follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HB tumor rupture might not be predictive of poor prognosis with the risk of peritoneal dissemination\/relapse, in which peritoneal perfusion with interleukin-2 could play a role.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2022.799307","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T16:54:01Z","timestamp":1648400041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective Analysis of Pediatric Hepatoblastoma With Tumor Rupture: Experience From a Single Center"],"prefix":"10.3389","volume":"10","author":[{"given":"Yu-Tong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian-Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/jhep.2003.50375","article-title":"Epidemiology of primary hepatic malignancies in U.S. children","volume":"38","author":"Darbari","year":"2003","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s00595-004-2766-9","article-title":"Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case","volume":"34","author":"Iida","year":"2004","journal-title":"Surg Today."},{"key":"B4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00383-006-1827-0","article-title":"Staged resection for a ruptured hepatoblastoma: a 6-year follow-up","volume":"23","author":"Madanur","year":"2007","journal-title":"Pediatr Surg Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zs\u00edros","year":"2010","journal-title":"J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2015.09.023","article-title":"The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model","volume":"52","author":"Czauderna","year":"2016","journal-title":"Eur J Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejca.2003.06.003","article-title":"Risk-adapted treatment for childhood hepatoblastoma final report of the second study of the International Society of Paediatric Oncology\u2013SIOPEL 2","volume":"40","author":"Perilongo","year":"2004","journal-title":"Eur J Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00383-010-2708-0","article-title":"Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT","volume":"27","author":"Hishiki","year":"2011","journal-title":"Pediatr Surg Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1002\/cncr.24667","article-title":"Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group","volume":"115","author":"Katzenstein","year":"2009","journal-title":"Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00247-018-4078-z","article-title":"2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)","volume":"48","author":"Towbin","year":"2018","journal-title":"Pediatr Radiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00247-006-0361-5","article-title":"2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group","volume":"37","author":"Roebuck","year":"2007","journal-title":"Pediatr Radiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e28549","DOI":"10.1002\/pbc.28549","article-title":"Tumor rupture in hepatoblastoma: a high risk factor?","volume":"67","author":"Pondrom","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/cncr.10632","article-title":"Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94","volume":"95","author":"Fuchs","year":"2002","journal-title":"Cancer."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/pbc.22088","article-title":"Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group","volume":"53","author":"Meyers","year":"2009","journal-title":"Pediatr Blood Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00383-016-4046-3","article-title":"Management of paediatric liver trauma","volume":"33","author":"van As","year":"2017","journal-title":"Pediatr Surg Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1002\/1097-0142(19930615)71:12<4067::AID-CNCR2820711243>3.0.CO;2-D","article-title":"Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions","volume":"71","author":"Viallat","year":"1993","journal-title":"Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12885-018-4581-5","article-title":"Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients","volume":"18","author":"Han","year":"2018","journal-title":"BMC Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1186\/s12885-021-09041-7","article-title":"Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/BF00730624","article-title":"The characterization of peritoneal and pleural exudate cells from malignant effusions","volume":"23","author":"Oka","year":"1993","journal-title":"Surg Today."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.799307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T16:54:05Z","timestamp":1648400045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.799307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":21,"alternative-id":["10.3389\/fped.2022.799307"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.799307","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-498600\/v1","asserted-by":"object"}]},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"799307"}}